Health
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test – News-Medical.net
Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic.
Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests.
The partnership will work towards CE marking of Aptamer Group’s AptaDx SARS-CoV-2 lateral flow rapid antigen test for professional use, to detect the SARS-CoV-2 spike protein antigen in anterior nasal swabs. Initial test analysis with laboratory samples has demonstrated excellent sensitivity…
-
Noosa News21 hours agoDog daycare program a TikTok hit for helping disabled find work, friends
-
Noosa News23 hours agoParkyn this, Parkyn that | Noosa Today
-
Noosa News23 hours agoR Tee in the running to be top dog
-
Noosa News21 hours agoAdvocates highlight sexual violence against older people, with Queensland elder abuse inquiry underway